[Skip to Content]
[Skip to Content Landing]

Year

Day

November 7, 2019
Original Investigation

Secondary 12-Month Ocular Outcomes of a Phase 1 Dosing Study of Bevacizumab for Retinopathy of Prematurity

Abstract Full Text
JAMA Ophthalmol. Published online November 7, 2019. doi:https://doi.org/10.1001/jamaophthalmol.2019.4488

This prospective cohort study evaluates ocular outcomes at 12 months’ corrected age in infants whose eyes received a dose of 0.625, 0.25, 0.125, 0.063, or 0.031 mg of bevacizumab for type 1 retinopathy of prematurity.

Individual Risk Prediction for Sight-Threatening Retinopathy of Prematurity Using Birth Characteristics

Abstract Full Text
open access
JAMA Ophthalmol. Published online November 7, 2019. doi:https://doi.org/10.1001/jamaophthalmol.2019.4502

This cohort study creates and validates an easy-to-use prediction model using only birth characteristics and describes a continuous hazard function for retinopathy of prematurity treatment.

Invited Commentary
JAMA Ophthalmology Clinical Challenge

Relapsing Optic Neuropathy and Multiple Cranial Neuropathies in a Middle-Aged Woman

Abstract Full Text
has active quiz
JAMA Ophthalmol. Published online November 7, 2019. doi:https://doi.org/10.1001/jamaophthalmol.2019.4410

A 55-year-old woman presents with decreased visual acuity, and magnetic resonance imaging shows thickening of the optic nerves and other areas of the brain. Over 5 years, she returns with multiple similar presentations. What would you do next?

Observation

SETD2 Mutation in an Aggressive Optic Nerve Glioma

Abstract Full Text
JAMA Ophthalmol. Published online November 7, 2019. doi:https://doi.org/10.1001/jamaophthalmol.2019.4511

This case report describes a 19-month-old boy with a SETD2 mutation in an aggressive optic nerve glioma.

×